Ann: Sirtex Trading Update, page-7

This below is from announcement...

Mr Andrew McLean, Chief Executive Officer of Sirtex Medical Limited commented “As a result of recent management initiatives, we anticipate higher sales in the second half, with ongoing targeted reductions in operating expenditure to drive business efficiencies and productivity gains, resulting in forecasted full year EBITDA in the range of $75-85 million. This compares to an underlying EBITDA1 of $61.5 million reported in the 2017 financial year.


Mr.market likes future!! I.e. Higher sales in second half....Not past or current half.....

Dyor...

We will see $20+ surely before results...